Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(26 sites)

United States

University of Florida, Gainesville, Florida

University of Chicago, Chicago, Illinois

Riley Hospital for Children, Indianapolis, Indiana

Memorial Sloan Kettering Cancer Center, New York, New York

Nationwide Children's Hospital, Columbus, Ohio

M.D. Anderson Cancer Center, Houston, Texas

Canada

The Hospital for Sick Children, Toronto

Denmark

Rigshospitalet, Copenhagen

France

Hopital pour enfants de la Timone, Marseille, Marseille

Germany

University Medical Center Hamburg-Eppendorf, Hamburg

Johannes Gutenberg-Universität, Mainz

University Hospital Regensburg, Regensburg

Hong Kong

Hong Kong Children's Hospital, Hong Kong

Queen Mary Hospital, Hong Kong

India

Tata Memorial Centre, Mumbai

Italy

Giannina Gaslini Hospital, Genoa, Genoa

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Milan

Ospedale Pediatrico Bambino Gesù, Rome

Spain

Hospital Sant Joan de Déu, Barcelona

Hospital Infantil Universitario Niño Jesús, Madrid

Hospital Universitario Virgen Del Rocío, Seville

Hospital Universitario y Politécnico La Fe, Valencia

United Kingdom

The Royal Glasgow Children's Hospital, Glasgow

Leeds General Infirmary, Leeds

The Royal Marsden, London

University Hospital Southampton, Southampton